Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Tech-Ausverkauf in Asien: TSMC und Co unter Druck (Der Aktionaer) +++ TAIWAN SEMICONDUCTOR Aktie -3,86%

RELMADA Aktie

 >RELMADA Aktienkurs 
3.82 EUR    (TradegateBSX)
Ask: 3.96 EUR / 630 Stück
Bid: 3.68 EUR / 682 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
RELMADA Aktie über LYNX handeln
>RELMADA Performance
1 Woche: +19,4%
1 Monat: +34,8%
3 Monate: +1,5%
6 Monate: -34,9%
1 Jahr: +28,2%
laufendes Jahr: +7,7%
>RELMADA Aktie
Name:  RELMADA THERAPEUT.DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US75955J4022 / A2PSZF
Symbol/ Ticker:  4E2 (Frankfurt) / RLMD (NASDAQ)
Kürzel:  FRA:4E2, ETR:4E2, 4E2:GR, NASDAQ:RLMD
Index:  -
Profil:  Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders. Its current pipeline centers on product candidates designed to address areas of significant unmet m..
>Volltext..
Marktkapitalisierung:  407.53 Mio. EUR
Unternehmenswert:  228.59 Mio. EUR
Umsatz:  -
EBITDA:  -61.61 Mio. EUR
Nettogewinn:  -59.6 Mio. EUR
Gewinn je Aktie:  -0.68 EUR
Schulden:  -
Liquide Mittel:  5.19 Mio. EUR
Operativer Cashflow:  -47.05 Mio. EUR
Bargeldquote:  25.99
Umsatzwachstum:  -
Gewinnwachstum:  -21.14%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  RELMADA
Letzte Datenerhebung:  16.11.26
>RELMADA Kennzahlen
Aktien/ Unternehmen:
Aktien: 106.7 Mio. St.
Frei handelbar: 86.99%
Rückkaufquote: -54.31%
Mitarbeiter: 17
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 185.56%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 2.03
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -59.68%
Eigenkaprendite: -64.66%
>RELMADA Peer Group
Gesundheit, Neurologische Erkrankungen/ Schlaganfälle, Psychische Erkrankungen/ Depressionen/ Schizophrenie, Onkologie/ Krebs- Behandlung
 
16.11.26 - 08:01
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer (GlobeNewswire EN)
 
Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01 Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01...
13.11.26 - 06:36
Relmada (RLMD) Q3 2026 Earnings Call Transcript (Fool)
 
Management highlighted a clean safety record and cash runway through 2029....
13.11.26 - 02:54
Relmada outlines NDV-01 IND submission by year-end 2026 with cash runway through 2029 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.11.26 - 23:00
Relmada Therapeutics GAAP EPS of -$0.12 beats by $0.02 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.11.26 - 13:02
Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London (GlobeNewswire EN)
 
CORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in London, UK, from November 16 - 19, 2026....
03.11.26 - 13:03
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026 (GlobeNewswire EN)
 
CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, November 12, 2026 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2026, and recent business progress....
11.09.26 - 16:01
Insiderhandel: Chief Financial Officer kauft Aktien von Relmada Therapeutics im Wert von 339150 USD (Insiderkauf)
 
Shenouda, Maged - Vorstand - Tag der Transaktion: 2026-09-10...
11.09.26 - 16:01
Insiderhandel: Chief Executive Officer kauft Aktien von Relmada Therapeutics im Wert von 418000 USD (Insiderkauf)
 
Traversa, Sergio - Vorstand - Tag der Transaktion: 2026-09-09...
11.09.26 - 16:01
Insiderhandel: Chief Executive Officer kauft Aktien von Relmada Therapeutics im Wert von 410000 USD (Insiderkauf)
 
Traversa, Sergio - Vorstand - Tag der Transaktion: 2026-09-10...
11.09.26 - 16:01
Insiderhandel: Chief Financial Officer kauft Aktien von Relmada Therapeutics im Wert von 504840 USD (Insiderkauf)
 
Shenouda, Maged - Vorstand - Tag der Transaktion: 2026-09-09...
25.08.26 - 17:16
Here′s Why Relmada Therapeutics (RLMD) Is a Great ′Buy the Bottom′ Stock Now (Zacks)
 
Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term....
14.08.26 - 07:24
Relmada (RLMD) Q2 2026 Earnings Call Transcript (Fool)
 
NDV-01 Phase 2 showed 95% complete response rates, with IND filing expected by year-end....
07.08.26 - 11:00
Relmada plans NDV-01 IND by end of 2026 as cash runway extends through 2029 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.08.26 - 23:24
Relmada übertrifft Gewinnprognose, doch Aktie fällt wegen Sorgen um Zeitplan (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
28.07.26 - 14:33
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer (GlobeNewswire EN)
 
CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer. Bipin will lead Relmada's corporate strategy, commercial planning, and business development activities, reporting directly to Chief Executive Officer Sergio Traversa....
16.07.26 - 13:06
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 (GlobeNewswire EN)
 
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress....
29.06.26 - 13:03
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes (GlobeNewswire EN)
 
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution....
18.06.26 - 20:33
Relmada′s Cancer Drug Candidate Sparks Fresh Bullish Call (Benzinga)
 
HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential. Latest Ratings for RLMD DateFirmActionFromTo Dec 2021SVB LeerinkMaintainsOutperform Nov 2021MizuhoInitiates Coverage OnBuy Oct 2020Goldman SachsDowngradesBuyNeutral View More Analyst Ratings for RLMD View the Latest Analyst Ratings Importance Rank:  1 read more...
11.06.26 - 13:03
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program (GlobeNewswire EN)
 
CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk's deep expertise in CNS translational science, neuroactive steroid biology, and clinical development will be instrumental in advancing sepranolone, Relmada's GABAA receptor modulator program targeting Prader-Willi Syndrome and other CNS indications....
19.05.26 - 14:54
Relmada Therapeutics: Aktie sinkt trotz solider Liquidität nach verfehlter Quartalsprognose (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Geschmack hängt nicht an unseren Bedürfnissen. Der Mann muß schon sehr gesittet sein, wenn er eine Frau nach Geschmack wählen soll. - Immanuel Kant
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!